Vaccines: This is what Dr Albert Sabin, creator of the oral polio vaccine had to say under oath… “… prevention [of polio] was long delayed by the erroneous conception qs the nature of the human disease based on misleading experimental models of the disease in monkeys.” Sabin, Albert, MD statement before the subcommittee on Hospitals and Health Care, Committee on Veterans Affairs, House of Representatives, April 26, 1984 serial no. 98-48
As monkeys gain polio via the respiratory system and humans via the digestive system, the creation of the polio vaccine was delayed by 29 years by primate research and resulted in the creation of a nasal spray which did nothing but damage the olfactory (smelling) ability of children it was given to.
"Animal models are not suitable for predicting the immunogenicity of therapeutic mAbs in humans, and transposition of the immunogenic potential of therapeutic antibodies in animals to the human situation has no scientific rationale, even in primates" - Loisel, S., M. Ohresser, M. Pallardy, D. Dayde, C. Berthou, G. Cartron, and H. Watier. 2007. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit Rev Oncol Hematol62 (1):34-42
"The relevance of animal testing, whether artificially created disease models or healthy animals for toxicology, has to be very seriously questioned for testing of human-specific biologic drugs," notes immunotherapeutics expert David Glover. "That's one of the key lessons of TGN1412." Peter Mitchell, Nature Biotechnology25, 485 - 486 (2007)
"...animal studies, even those conducted in non-human primates, have limited predictive power for immunogenicity in humans." Bugelski and Treacy, Current Opinions in Molecular Therapeutics, 6:10-16.
"...it was generally accepted that predicting human immunogenicity, even in non-human primates was rare and thus, the predictive power of preclinical immunogenicity is low." Bugelski & collaborators from Centocor, US FDA, GlaxoSmithKline, Amgen & Pfizer. Predictive Power of Preclinical Data for Human Immunogenicity of Macromolecules: Proceedings of a Roundtable Discussion. (Discussion Macromolecules: Proceedings of a Roundtable Discussion. (Discussion sponsored by the Immunotoxicology Technical Committee Health & Environmental Sciences Institute/ International Life Sciences Institute) 2004
This sums it up..."If you want your vaccine to work in a human, you’d better get it into a human, quickly. Otherwise you’re going to spend a lot of time with animal studies and never be able to predict what it will do in people." Prof. Bob Edelman, June 2002.
http://www.antigenics.com/whitepapers/qs21_adjuvant.html
AIDS "To date, 85 candidate AIDS vaccines have been tested in 197 clinical trials, comprising several main types — from inactivated virus vaccines through DNA plasmids to recombinant proteins and viruses. Just 12% of these trials have reached Phase II, only seven (3.5%) have reached Phase III, and alto- gether, 18 trials were prematurely terminated. None has been successful." An assessment of the role of chimpanzees in AIDS vaccine research. Bailey J. Altern Lab Anim. 2008